+++ Einfach investieren ▪ mit Kapitalschutz oder Teilschutz ▪ raiffeisenzertifikate.at ▪ jetzt in Zeichnung +++ -w-
18.04.2024 07:02:17

Sartorius Stedim Biotech publishes unaudited first quarter results for 2024

Sartorius Stedim Biotech SA / Key word(s): Quarter Results
Sartorius Stedim Biotech publishes unaudited first quarter results for 2024

18-Apr-2024 / 07:02 CET/CEST

 
Aubagne, France | April 18, 2024

Sartorius Stedim Biotech publishes unaudited first quarter results for 2024
 
  • Sales revenue of 667 million euros, in constant currencies1 - 9.4 percent organically1and - 6.7 percent including acquisitions2(reported: - 8.2 percent)
  • Order intake up 13.9 percent to 676 million euros (reported: 12.5 percent) with significant growth in recurring business, while demand from China remains weak; book-to-bill ratio slightly above 1
  • Underlying EBITDA1 at 191 million euros, resulting margin at 28.6 percent; net profit of 56 million euros
  • Full-year outlook confirmed; uncertainties remain high due to the global political and economic situation

In a continuously challenging market environment, Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, closed its first quarter largely within the bandwidth of expectations recording an increase in order intake and a decline in sales revenue compared with a significantly stronger prior-year period. For the full year, the company continues to anticipate business momentum to gradually pick up from quarter to quarter and forecasts sales revenue growth in the mid to high single-digit percentage range.

“Overall, the first three months showed the projected continued recovery, however the dynamics across our portfolio and regions were mixed. Demand continued to normalize particularly in our recurring core business with consumables, where orders are picking up, signaling that customers have made further progress in destocking. In addition, it is encouraging to see that the business with cell and gene therapy customers, a major strategic focus point, has continued to perform strongly. On the other hand, customer investment into hardware and systems remained muted, especially in China and to some extent also in Europe, which led to soft development in our equipment business. In terms of profitability, we achieved a robust EBITDA margin, and our ongoing efficiency programs should deliver further benefits later in the year,” said René Fáber, CEO of Sartorius Stedim Biotech.

Business development1
In the first quarter of the fiscal year, Sartorius Stedim Biotech recorded an increase in order intake1 of 13.9 percent in constant currencies (reported: 12.5 percent) to 676 million euros, with growth coming from all regions except China. In view of advanced inventory reductions on the part of customers, business has been recovering since the end of the third quarter of 2023. Order volume was slightly above sales revenue in the first three months of 2024, which stood at 667 million euros, down 6.7 percent in constant currencies (organic: - 9.4 percent; reported: - 8.2 percent) compared with the prior-year period’s strong figure. This includes a growth contribution from acquisitions2 of 2.7 percentage points.

From a regional perspective, the normalization of demand was visible in all business regions: The EMEA3 region recorded an increase in order intake of 8.6 percent with sales revenue down by 3.8 percent. In the Americas region, order intake grew at a double-digit rate of 29.4 percent, while sales revenue declined by 8.6 percent. In Asia/Pacific, order intake increased by 3,2 % in constant currencies, while the continued market weakness in China led to a decline in sales revenue (- 8.8 percent).

Underlying EBITDA decreased by 13.2 percent to 191 million euros in the first three months, with positive product mix effects and cost base adjustments partially compensating the negative volume development. The EBITDA margin reached 28.6 percent (prior-year period: 30.3 percent).

Underlying net profit1 was 84 million euros, compared with 131 million euros in the first quarter of 2023. Net profit amounted to 56 million euros against 111 million euros in the previous year’s period. Underlying earnings per share stood at 0.86 euros (prior-year period 1.43 euros) and earnings per share at 0.58 euros (prior-year period: 1.21 euros). The number of employees worldwide was 10,493 as of March 31, 2024, after 11,581 in the prior-year quarter (December 31, 2023: 10,662 people).

Key financial indicators
Sartorius Stedim Biotech’s key financial indicators remain at a sound level. Equity was 3,867 million euros as of March 31, 2024, while the equity ratio1 increased to 45.8 percent (December 31, 2023: 2,673 million euros and 34,5 percent, respectively), mainly as a result of the equity measures successfully completed at the beginning of February 2024. Gross debt was down to 3,189 million euros (December 31, 2023: 3,682 million euros) and net debt down to 2,494 million euros, resulting in a reduced ratio of net debt to underlying EBITDA1 of 3.3 (December 31, 2023: 3,565 million euros and 4.5 respectively).

Mainly due to lower earnings, net operating cash flow totaled 55 million euros, compared with 166 million euros in the prior-year period. Cash flow from investing activities amounted to - 109 million euros after - 116 million euros in the first quarter of 2023. The ratio of capital expenditures (capex) to sales revenue was 16.4 percent compared with 16.0 percent in the prior-year period.

Outlook for fiscal 2024
Management confirms its expectations for the current fiscal year and continues to anticipate a moderate first half of 2024 and increasing business momentum in the course of the year. In addition, business performance could also be affected by increasing geopolitical tensions and economic slowdowns.

Accordingly, consolidated Group sales revenue is projected to increase in the mid to high single-digit percentage range, including a contribution of around 2 percentage points from acquired businesses. In terms of profitability, management anticipates a rise in the underlying EBITDA margin to more than 30 percent compared with the previous year’s figure of 28.3 percent. The above-average profitability of the Polyplus business should have a slightly positive effect on the margin development. The ratio of capital expenditure to sales revenue is expected to be around 13 percent (prior year: 17.1 percent), and the ratio of net debt to underlying EBITDA1 slightly below 2.5.
Forecasts have been prepared based on historical information and are consistent with accounting policies. All forecast figures are based on constant currencies, as in the past years. Management points out that the dynamics and volatilities in the industry have increased significantly in recent years. In addition, uncertainties due to the changed geopolitical situation, such as the emerging decoupling tendencies of various countries, are playing a greater role. This results in higher uncertainty when forecasting business figures.

1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry.
 
  • Constant currencies: figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
  • Organic: organic growth figures exclude the impact from changes in exchange rates and changes in the scope of consolidation
  • Order intake: all customer orders contractually concluded and booked during the respective reporting period
  • Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items
  • Underlying net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate
  • Equity ratio: equity in relation to the balance sheet total
  • Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period
2 Acquisition of Polyplus
3 EMEA = Europe, Middle East, Africa
This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.
Conference call
Dr. René Fáber, CEO of the Sartorius Stedim Biotech Group, will discuss the company’s first quarter results with analysts and investors in a conference call at 1.00 p.m. CEST on April 18, 2024.
Register here: https://sar.to/Q1_IR_SSB_Registration
Financial calendar
July 19, 2024                     Publication of the first-half figures (January to June 2024)
October 17, 2024            Publication of the nine-month figures (January to September 2024)


Key Performance Indicators for the First Quarter of 2024
 
in millions of €
unless otherwise specified 		Q1
2024		 Q1
2023		 ∆ in %   Reported ∆ in % cc1
Order Intake and Sales Revenue        
Order intake² 676.3 601.3 12.5 13.9
Sales revenue 666.9 726.1 -8.2 -6.7
  • EMEA³
 284.4 296.8 -4.2 -3.8
  • Americas³
 233.4 258.2 -9.6 -8.6
  • Asia | Pacific³
 149.1 171.1 -12.8 -8.8
Results        
EBITDA4 191.0 220.1 -13.2  
EBITDA margin4 in % 28.6 30.3    
Underlying net profit5 84.1 131.4 -36.0  
Underlying earnings per share5 in € 0.86 1.43 -39.4  
Net profit6 56.1 111.1 -49.5  
Earnings per share⁶ in €  0.58 1.21 -52.2  

1 cc = constant currencies: Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
2 All customer orders contractually concluded and booked during the respective reporting period
3 According to customer location
4 Underlying EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items
5 Relevant / underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and
    amortization, as well as based on a normalized financial result and normalized tax rate
6 After non-controlling interest

Figures are not audited nor reviewed.


Reconciliation
in millions of € Q1
2024   		Q1
2023    
EBIT (operating result) 110.0 153.7
Extraordinary items 10.6 17.8
Depreciation & amortization 70.4 48.6
Underlying EBITDA 191.0 220.1

Figures are not audited nor reviewed.
 
In millions of €,
unless otherwise specified		 Q1
2024   		Q1
2023    
EBIT (operating result) 110.0 153.7
Extraordinary items 10.6 17.8
Amortization | IFRS 3 29.7 16.8
Normalized financial result1 -35.5 -10.3
Normalized income tax (26%)2 -29.9 -46.3
Underlying net result after taxes 85.0 131.8
Non-controlling interest -0.9 -0.4
Underlying net result after taxes and non-controlling interest 84.1 131.4
Underlying earnings per share (in €) 0.86 1.43

1 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities and change in valuation of earn-out liability
2 Normalized income tax based on the underlying profit before taxes and amortization
Figures are not audited nor reviewed.

 
In millions of €,
unless otherwise specified		 Q1
2024   		Q1
2023
Gross debt 3,188.8 1,306.8
-  Cash and cash equivalents 695.1 94.0
Net debt 2,493.8 1,212.8
     
Underlying EBITDA (12 months) 756.3 1,137.8
+ Pro forma EBITDA (12 months) 7.2 7.3
Pro forma underlying EBITDA (12 months) 763.5 1,145.0
Ratio of net debt to underlying EBITDA 3.3 1.1
 
In millions of €,
unless otherwise specified		 Q1
2024 		Q1
2023   
Sales revenue 666.9 726.1
Capital expenditures 109.2 115.8
Capital expenditures as % of sales revenue 16.4 16.0

Figures are not audited nor reviewed

A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros. By the end of 2023, more than 10,600 employees were working for customers around the globe.

Visit our newsroom and follow Sartorius Stedim Biotech on LinkedIn.
Contact
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686
petra.kirchhoff@sartorius.com
 
Attachment

File: MediaRelease_SSB_Q1_2024_en

Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
EQS News ID: 1883101

 
End of Announcement - EQS News Service

1883101  18-Apr-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1883101&application_name=news&site_id=smarthouse

Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!

Nachrichten zu Sartorius Stedim Biotechmehr Nachrichten

Analysen zu Sartorius Stedim Biotechmehr Analysen

22.10.24 Sartorius Stedim Biotech Neutral UBS AG
17.10.24 Sartorius Stedim Biotech Buy Goldman Sachs Group Inc.
03.10.24 Sartorius Stedim Biotech Buy Goldman Sachs Group Inc.
03.10.24 Sartorius Stedim Biotech Neutral UBS AG
02.09.24 Sartorius Stedim Biotech Outperform RBC Capital Markets
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Newssuche

GO

Aktien in diesem Artikel

Sartorius Stedim Biotech 183,70 -2,13% Sartorius Stedim Biotech

Börse aktuell - Live Ticker

Letzter Handelstag des Jahres: ATX kaum verändert -- DAX etwas tiefer -- Nikkei 225 gibt letztlich nach
Der heimische Aktienmarkt bewegt sich im Montagshandel um die Nulllinie, während der deutsche Leitindex etwas darunter liegt. An den asiatischen Aktienmärkten waren am Montag gemischte Vorzeichen zu sehen.

Nachrichten

Aktien ATX  DAX  EuroStoxx 50  Dow Jones  NASDAQ 100  Nikkei 225  S&P 500 

Kontakt  - Impressum - Werbung

Sitemap  - Datenschutz  - Disclaimer  - AGB  - Privatsphäre-Einstellungen